SEC Form 6-K Summary: GlaxoSmithKline plc
Business Context and Reporting Period
This filing is a Form 6-K Report of Foreign Issuer submitted by GlaxoSmithKline plc for the period ending April 20, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports on specific share transactions.
Material Changes and Transaction Details
The filing discloses three separate transactions involving the acquisition of American Depositary Shares (ADSs) on April 17, 2018, executed on the New York Stock Exchange (XNYS). All transactions were acquisitions resulting from the re-investment of dividends paid to shareholders on April 12, 2018. The specific details are as follows:
- Mr. N. Hirons (SVP, Global Ethics & Compliance): Acquired 23.721 ADSs at a price of $40.534 per share.
- Mr. B. McNamara (CEO, Consumer Healthcare): Acquired 535.096 ADSs at a price of $40.534 per share.
- Mr. D. E. Troy (SVP & General Counsel): Acquired 2,863.339 ADSs at a price of $40.534 per share.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. The scope is limited to the statutory disclosure of the aforementioned share acquisitions.
Key Facts for Investor Verification
- Verify the dividend reinvestment plan terms applicable to the April 12, 2018 dividend payment.
- Confirm the total number of ADSs held by the named executives post-transaction.
- Note that the transaction price of $40.534 reflects the market price on the execution date of April 17, 2018.
- Ensure these transactions are consistent with the company's insider trading policy and window periods.